Headline EventAnalyzer: Daily Market Movers (4 Sep 2009)
Source EP Vantage
Company Facet Biotech, Allos Therapeutics, Array BioPharma, Dainippon Sumitomo Pharma, Diamyd Medical, Human Genome Sciences, Jazz Pharmaceuticals, SIGA Technologies 
Date September 07, 2009
 

EvaluatePharma’s EventAnalyzer delivers a daily global round up of key events driving company valuations. Detailing the previous day’s top 15 market gains and losses, aligned with significant news flow driving share prices, the EventAnalyzer keeps you in touch with the latest market moves.

Top 15 Gains (%) - ranked on change in share price

      Performance: Fri 04 Sep vs. Thu 03 Sep    
Rank   Company   Listed Currency   Share Price Change   Market Cap (US$m)   Market Cap Change   Notes on Change  
1   Facet Biotech   USD   +74%   378   +161   4 Sep: Company receives a hostile takeover offer from Biogen Idec at $14.50 per share, having previously rejected a $15 per share offer; Biogen's offer values Facet at $355m, only around $45m higher than Facet's estimated cash of $310m; Facet's shares closed at $15.38 suggesting that the market expects Biogen will eventually have to raise its bid to close the deal.  
2   Jazz Pharmaceuticals   USD   +32%   287   +70   4 Sep: Shares rise on 5.5x average daily trading volume.  
3   Diamyd Medical   SEK   +21%   162   +28   3 Sep: Company reports positive 4-year follow-up data from a phase II trial of type 1 diabetes patients who received just two injections of Diamyd vaccine.  
4   SIGA Technologies   USD   +13%   282   +33   3 Sep: Company's common stock listing transfers from the Nasdaq Capital Market to the Nasdaq Global Market, providing greater liquidity.  
5   The Medicines Company   USD   +8%   583   +42    
6   Human Genome Sciences   USD   +6%   3143   +187   4 Sep: Company announces the publication of an article in the journal of Arthritis Care & Research which supports the use of the systemic lupus erythematosus (SLE) Responder Index as a primary efficacy endpoint, selected by the company in two phase III trials of lead pipeline candidate, Benlysta.  
7   Allos Therapeutics   USD   +5%   707   +35   Shares rebound, having initially dropped 4% on 3 Sep despite an FDA advisory committee vote 10-4 in favour of approval for Folotyn to treat T-cell lymphoma, as some committee members and analysts expressed concern over the drug's relatively low response rate.  
8   Omega Pharma   EUR   +5%   962   +44    
9   Geron   USD   +4%   656   +27    
10   Incyte   USD   +4%   678   +27    
11   Dendreon   USD   +3%   2755   +93    
12   Ipsen   EUR   +3%   4189   +140    
13   Alexion Pharmaceuticals   USD   +3%   4041   +125    
14   Abraxis BioScience   USD   +3%   1041   +32    
15   MannKind   USD   +3%   889   +26    

Excludes companies with a market cap. movement of less than US$25m.


Top 15 Losses (%) - ranked on change in share price

      Performance: Fri 04 Sep vs. Thu 03 Sep    
Rank   Company   Listed Currency   Share Price Change   Market Cap (US$m)   Market Cap Change   Notes on Change  
1   Array BioPharma   USD   -23%   140   -42   4 Sep: Company's lead compound ARRY-162 fails to meet primary endpoint in a phase II rheumatoid arthritis trial following a strong placebo response; full data of trial expected by 2010.  
2   Dainippon Sumitomo Pharma   JPY   -6%   3965   -256   3 Sep [post market]: Company confirms that it is acquiring Sepracor for $23 per share, or $2.6bn in total, in a deal to increase its presence in the US and add a US sales force ahead of the expected approval of its lead drug, lurasidone, a treatment for schizophrenia. Analysts, however, question whether the group might have over paid, given the near term patent expiries of many of Sepracor's lead products, including sleep drug Lunesta.  
3   Novavax   USD   -5%   501   -29    
4   OPKO Health   USD   -5%   659   -38    
5   Shionogi   JPY   -4%   7595   -345    
6   Alapis   EUR   -4%   728   -28    
7   Tsumura   JPY   -2%   2300   -51    
8   Daiichi Sankyo   JPY   -2%   14022   -301    
9   Intercell   EUR   -2%   1628   -31    
10   Hisamitsu Pharmaceutical   JPY   -2%   3388   -59    
11   Ajinomoto   JPY   -2%   6484   -109    
12   Toray Industries   JPY   -1%   7484   -102    
13   Ono Pharmaceutical   JPY   -1%   5665   -63    
14   Aspen Pharmacare   ZAR   -1%   2580   -27    
15   Kyowa Hakko Kirin   JPY   -1%   6407   -54    

Excludes companies with a market cap. movement of less than US$25m.

Disclaimer:
 

This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
EP Vantage SM ©2010 EP Vantage Ltd